assignment
Not Recruiting

Phase III Randomized Trial of High-Dose Interferon or Ipilimumab Versus Pembrolizumab in Patients with High-Risk Resected Melanoma

Trial ID
2024-516881-12-00
Protocol
CTRIAL-IE 16-12

Register record, history and transparency: CTIS.eu

Trial statistics

science
1
test molecule
location_city
1
research site
public
1
country
medical_information
1
disease
person_search
1
investigator

Diseases & Conditions

Malignant melanoma

Objectives

The primary objective of this Phase III randomized trial is to compare **overall survival (OS)** of patients with resected Stage III and IV melanoma treated with either high dose interferon alfa-2b or ipilimumab versus **MK-3475 (pembrolizumab)**. This comparison is crucial for determining the most effective treatment option for improving survival outcomes in patients with high-risk resected melanoma. Additionally, among patients who are **PD-L1 positive**, the study aims to compare OS specifically within this subgroup, as well as to evaluate **relapse-free survival (RFS)** across the treatment options.

The secondary objectives include: - Estimating OS and RFS for patients who are PD-L1 negative or indeterminate, and comparing these outcomes between the two treatment arms within PD-L1 positive and negative subgroups. The study will also assess the safety and tolerability of the regimens. - Banking tissue and whole blood for future correlative studies, evaluating PD-L1 expression through immunohistochemistry, and assessing the impact of treatment-related side effects on quality of life. Pharmacokinetic and anti-drug antibody testing will be conducted on all patients receiving pembrolizumab. - Translational objectives involve evaluating the association between TCRβ variable gene (TRBV) haplotype and Grade 3-4 immune-related adverse events among Stage III melanoma patients treated with adjuvant ipilimumab or pembrolizumab, and describing the TRBV haplotype distribution.

Participants

The clinical trial involves a total of **1342 participants** diagnosed with **high-risk resected melanoma**. The study population includes both male and female subjects, aged **18 years and older**, with no vulnerable populations selected. Participants were chosen based on specific disease-related criteria, including having completely resected melanoma of cutaneous origin or unknown primary, classified as Stage IIIA (N2a), IIIB, IIIC, or Stage IV. Individuals with melanoma of ocular origin or a history of brain metastases were excluded. All participants were required to have a documented disease-free status through physical examination and imaging studies prior to registration. Lifestyle factors such as diet and physical activity were not specified as part of the selection criteria. The trial does not focus on any particular lifestyle considerations, and the selection was primarily based on clinical and laboratory criteria, ensuring adequate bone marrow, hepatic, and renal function, among others. Participants were also required to have a Zubrod Performance Status of 1 or less and, if applicable, stable HIV status with adequate CD4 counts. The trial includes individuals who can complete quality of life assessments in English, Spanish, or French.

Plans and Procedures

The clinical trial is a **Phase III randomized** study designed to compare the efficacy of **pembrolizumab** with either high-dose interferon alfa-2b or ipilimumab in patients with high-risk resected melanoma. The trial employs a **double-blind, controlled** methodology to ensure unbiased results. The estimated duration of the trial is from August 2017 to August 2027, with a maximum treatment period of 52 weeks for each participant. Participants will be randomly assigned to receive either pembrolizumab or the physician/patient choice of high-dose interferon or ipilimumab, with the primary endpoints being overall survival, relapse-free survival, and progression/relapse.

The sequence of study visits begins with an inclusion (screening) visit, where eligibility is confirmed through a complete physical examination, imaging studies, and laboratory tests. Participants must have a disease-free status documented within 42 days prior to registration. Following the screening, eligible participants will undergo randomization and commence treatment. Follow-up visits will be scheduled at regular intervals to monitor the participants' health status, treatment adherence, and any adverse events. The end-of-study visit will occur after the completion of the treatment period or upon early termination from the study.

Participant involvement is expected to last up to 52 weeks, with conditions for early termination including disease progression, unacceptable toxicity, or withdrawal of consent. Participants must meet specific inclusion criteria, such as having completely resected melanoma of cutaneous or unknown primary origin, and must not have a history of brain metastases. Adequate organ function and performance status are also required. The trial aims to provide valuable insights into the comparative effectiveness of pembrolizumab versus other treatment options in improving survival outcomes for patients with high-risk resected melanoma.

Treatment

The clinical trial involves the administration of **KEYTRUDA** (pembrolizumab), a **concentrate for solution for infusion**. This experimental medication is provided in a concentration of 25 mg/mL and is administered via the **intravenous** route. The maximum daily dose is 200 mg, with a total maximum dose of 3600 mg over the course of the treatment. The treatment period is set to a maximum of 52 weeks. Pembrolizumab is a humanized anti-PD-1 monoclonal antibody of the IgG4/kappa isotype, featuring a stabilizing S228P sequence alteration in the Fc region. The pharmaceutical form is specifically designed for infusion, ensuring precise delivery of the active substance.

In addition to the experimental treatment, the study includes a comparator treatment, which consists of the physician/patient choice between high-dose interferon alfa-2b or ipilimumab. These non-experimental treatments serve as standard-of-care therapies for patients with high-risk resected melanoma. The choice of comparator treatment is determined based on clinical judgment and patient preference, providing a comprehensive approach to evaluating the efficacy of pembrolizumab in comparison to established therapies.

Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the treatment protocol. The administration of pembrolizumab and the comparator treatments is conducted under strict clinical supervision, with regular assessments to evaluate treatment response and manage any potential adverse effects. The trial aims to compare overall survival and relapse-free survival among patients with resected Stage III and IV melanoma, with a particular focus on those who are PD-L1 positive.

Efficacy

Efficacy in this clinical trial will be assessed using several primary endpoints, including **Progression/Relapse**, **Relapse-Free Survival (RFS)**, **Overall Survival (OS)**, and **Performance Status**. These endpoints are critical in evaluating the effectiveness of the treatment options being compared: high dose interferon, ipilimumab, and MK-3475 (pembrolizumab) in patients with resected Stage III and IV melanoma.

The primary objective is to compare the OS of patients treated with either high dose interferon or ipilimumab versus MK-3475 (pembrolizumab). Additionally, among patients who are PD-L1 positive, the trial aims to compare the OS between the same treatment groups. RFS will also be compared among the treatment groups to assess the duration patients remain free from disease relapse.

Data collection for these endpoints will involve regular monitoring and assessments throughout the trial duration. The trial is designed to ensure comprehensive evaluation of the treatment efficacy, with a focus on survival outcomes and disease progression metrics. The trial is expected to conclude by August 2027, with recruitment having started in August 2017.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Step 1 Registration: Disease Related Criteria: Patients must have completely resected melanoma of cutaneous origin or of unknown primary. Patients must be classified as Stage IIIA (N2a), IIIB, IIIC, or Stage IV melanoma. Patients with non-ulcerated T1b N1a disease are not eligible. Patients with melanoma of mucosal or other non-cutaneous origin are eligible. Patients with melanoma of ocular origin are not eligible. Patients with a history of brain metastases are ineligible.
  • Step 1 Registration: Disease Related Criteria: Patients are eligible for this trial either at initial presentation of their melanoma or at the time of the first detected nodal, satellite/in-transit, distant metastases, or recurrent disease in prior lymphadenectomy basin or distant site. Nodal, satellite/in-transit metastasis, distant metastases or disease in a prior complete lymphadenectomy basin must have been confirmed histologically by H & E stained slides.
  • Step 1 Registration: Disease Related Criteria: Patients with multiple regional nodal basin involvement are eligible. Gross or microscopic extracapsular nodal extension is permitted.
  • Step 1 Registration: Disease Related Criteria: Patients at initial presentation of melanoma must undergo an adequate wide excision of the primary lesion, if present. Patients with previously diagnosed melanoma must have had all current disease resected with pathologically negative margins and must have no evidence of disease at the primary site or must undergo re-resection of the primary site. A full lymphadenectomy is required for all node-positive patients including those with positive sentinel nodes. Patients with recurrent disease who have had a prior complete lymphadenectomy fulfill this requirement as long as all recurrent disease has been resected. For all patients, all disease must have been resected with negative pathological margins and no clinical, radiologic, or pathological evidence of any incompletely resected melanoma. Patients must be registered within 98 days of the last surgery performed to render the patient free of disease.
  • Step 1 Registration: Specimen Submission Criteria: Patients must have available and be willing to submit a minimum of 5 unstained slides from primary, lymph node, or metastatic site to determine PD-L1 expression.
  • Step 1 Registration: Specimen Submission Criteria: Patients must be offered the opportunity to participate in specimen banking.
  • Step 1 Registration: Specimen Submission Criteria: Patients must be willing to have blood draws for PK/ADA ( MK-3475 arm).
  • Step 1 Registration: Prior/Concurrent Therapy Criteria: Patients may have received prior radiation therapy, including after the surgical resection. All AEs associated with prior surgery and radiation therapy must have resolved to ≤ Grade 1 prior to registration.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must be ≥ 18 years of age.
  • Step 1 Registration: Clinical/Laboratory Criteria: All patients must have disease-free status documented by a complete physical examination and imaging studies within 42 days prior to registration. Refer to protocol for imaging requirements.
  • Step 1 Registration: Clinical/Laboratory Criteria: All patients must have a CT or MRI of the brain within 90 days prior to registration (with intravenous contrast (unless contraindicated)).
  • Step 1 Registration: Clinical/Laboratory Criteria: Adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500 mcL; platelets ≥ 100,000/mcL; Hemoglobin ≥ 10 g/dL.
  • Step 1 Registration: Clinical/Laboratory Criteria: Adequate hepatic function as evidenced by the following: total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except Gilbert’s Syndrome, who must have a total bilirubin < 3.0 mg/dL), and SGOT (AST) and SGPT (ALT) and alkaline phosphatase ≤ 2 x IULN.
  • Step 1 Registration: Clinical/Laboratory Criteria: Adequate renal function as evidenced by ONE of the following: serum creatinine ≤ IULN OR measured or calculated creatinine clearance ≥ 60 mL/min.
  • Step 1 Registration: Clinical/Laboratory Criteria: LDH performed within 42 days prior to registration.
  • Step 1 Registration: Clinical/Laboratory Criteria: Zubrod Performance Status ≤ 1.
  • Step 1 Registration: Clinical/Laboratory Criteria: A baseline ECG performed within 42 days of registration that is normal or considered not clinically significant.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients known to be HIV positive are eligible if they meet the following criteria within 30 days prior to registration: stable and adequate CD4 counts (≥ 350 mm3), and serum HIV viral load of < 25,000 IU/ml. Patients may be on or off anti-viral therapy so long as they meet the CD4 count criteria.
  • Step 1 Registration: Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 120 days after the last dose of study medication.
  • Step 1 Registration: Patients who are able to complete questionnaires in English, Spanish or French must participate in the quality of life assessments. (Those patients who cannot complete the quality of life questionnaires can be registered to S1404.
  • Step 2 Registration (Randomization): Women of childbearing potential must plan to have a urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication.
  • Step 2 Registration (Randomization): Patients who are known to have a change in eligibility status after Step 1 registration are not eligible for Step 2 registration.
cancel

Exclusion Criteria

  • Step 1 Registration: Prior/Concurrent Therapy Criteria: Patients must not have received neoadjuvant treatment for their melanoma. Patients must not have had prior immunotherapy including, but not limited to ipilimumab, interferon alfa-2b, high dose IL-2, PEG-IFN, anti-PD-1, anti-PD-L1 intra-tumoral or vaccine therapies. Patients must not be planning to receive any of the prohibited therapies listed in protocol Section 7.2 during the screening or treatment phases of the study.
  • Step 1 Registration: Clinical/Laboratory Criteria: No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, lobular carcinoma of the breast in situ, atypical melanocytic hyperplasia or melanoma in situ, adequately treated Stage I or II cancer (including multiple primary melanomas) from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years.
  • Step 1 Registration: Prior/Concurrent Therapy Criteria: Patients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, surgery or other therapy after Step 2 registration.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must not have a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must not have an active infection requiring systemic therapy.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must not have received live vaccines within 42 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must not have known active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection prior to registration.
  • Step 1 Registration: Clinical/Laboratory Criteria: Patients must not have a history or current evidence of any condition, therapy or laboratory abnormality that might confound the trial results, interfere with the patient's participation for the full duration of the trial, or indicate that participation in the trial is not in the patient's best interests, in the opinion of the treating investigator.

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Ireland IrelandNot Recruiting24 Aug 20173

Sites & Investigators

Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
KEYTRUDA 25 mg/mL concentrate for solution for infusion
TestCONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS20052PRD4323105

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Pembrolizumab
477 trials

Also investigated for

Non-small cell lung cancer 88Malignant melanoma 39Non-small cell lung cancer metastatic 33Neoplasm 28